Cell Line Genetics Marks 7,500 Quality Assurance Cases in the Field of Stem Cell Research & Regenerative Medicine

Leader in Stem Cell Quality Assurance Passes Major Milestone, Expands Management and Scientific Team

MADISON, Wis. & NEW YORK--(BUSINESS WIRE)--Cell Line Genetics, Inc. (“CLG”), a leader in Stem Cell Quality Assurance (“QA”) services and products, announced today that it has performed QA services on over 7,500 stem cell samples. The company concurrently announced significant additions to both its management and scientific teams: Robert Margolin has been appointed to Director of Marketing, and the company expanded its research and product development team in Madison, Wisconsin.

“While we are very pleased to reach this 7,500 case milestone, we see this not as an endpoint, but as just the beginning”

“We are proud of our team’s achievements,” commented Roberto “Rob” Herrera, Cell Line Genetics’ Chief Business Officer. “This milestone reflects our leadership in the regenerative medicine QA space, and moreover, speaks to the loyalty of our customers, to our scientific and operational excellence, and to a healthy market demand. We continue to grow as a company and strengthen our management and R&D presence, enabling CLG to actively increase its marketing capabilities and pursue new proprietary and collaborative product opportunities.”

Mr. Margolin was previously the Associate Director of the Genetics Policy Institute, where he played an instrumental role in organizing the annual World Stem Cell Summit and in publishing the annual World Stem Cell Report. Prior to that he was an analyst and business development executive at Burrill Life Sciences Media Group.

“While we are very pleased to reach this 7,500 case milestone, we see this not as an endpoint, but as just the beginning,” stated Julie Johnson., Cell Line Genetics’ Director of Laboratory Operations. “With the recent growth of our scientific team, we can continue not only to provide a variety of QA services, we can accelerate the development of new technologies and increase our focus on major long-term goals, as well.”

Additionally, Cell Line Genetics announced that it will be exhibiting at the 9^th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Toronto from June 15^th to June 18^th. More information on the event is available at www.isscr.org/meetings/index.cfm.

About Cell Line Genetics, Inc.

Cell Line Genetics, Inc. is a leading provider of multi-species Quality Assurance services and products for the Stem Cell and Regenerative Medicine market. Focusing on embryonic, adult and induced pluripotent stem cells, CLG provides a variety of multispecies QA services for research, preclinical and clinical studies. Headquartered in Madison, Wisconsin and with offices in New York City, CLG’s clients include leading universities and research institutes, as well as biotechnology and pharmaceutical companies.

For a complete list of CLG products and services please visit www.clgenetics.com.